Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Phase of Trial: Phase III
Latest Information Update: 20 Oct 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 5
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 07 Apr 2017 Planned End Date changed from 22 Jan 2018 to 25 May 2018.
- 22 Sep 2016 Status changed from not yet recruiting to recruiting.